Skip to main content
. Author manuscript; available in PMC: 2020 Dec 29.
Published in final edited form as: Mol Cancer Ther. 2020 Mar 18;19(6):1232–1242. doi: 10.1158/1535-7163.MCT-19-0885

Figure 6. MPL/TDCM-elicited anti-tumor responses depend on TNFα.

Figure 6.

(A) Mice were challenged with 2.5 × 104 TA3-Ha cells ± MPL/TDCM i.p. on d0. Mice received aminoguanidine (400 mg/kg) i.p. daily from d0–8 (n=11–13/group; pooled from 2 independent experiments). (B) TA3-HA cells were cultured in medium alone, or in the presence rabbit complement (5 or 2%), d14 sera from MPL/TDCM-treated mice (5 or 2%), recombinant TNF-α (10 ng/ml), or a combination of these, as indicated, for 18 hrs. Cells were incubated with Live/Dead viability stain and Countbright beads, washed and stained with Annexin V, with the percentage (top panel) and number (lower panel) of live (A, AnnexinVnegLive/Deadneg) cells recovered. Hashtags (#) indicate significant differences from medium control, and asterisks (*) indicate differences among individual groups. Similar results obtained in 2 independent experiments. (C) Mice were challenged with 2.5 × 104 TA3-Ha cells ± MPL/TDCM on d0. Anti-TNFα antibody was given on days 2 (200 μg), 4 (200 μg), and 6 (100 μg) post-tumor challenge i.p., with survival assessed (n=9–11/group). Data pooled from two independent experiments, with similar results obtained in each. In A and C, p values indicate Log-rank results for pooled data plotted in survival curves.